Tepha raises $4.3m for biomaterial development:
This article was originally published in Clinica
Executive Summary
Tepha, a private developer of medical devices used in surgical repair and regenerative medicine, has secured $4.3m in financing from The Vertical Group, Integra Ventures and Novartis Venture Fund. The Cambridge, Massachusetts-based company says it will use the proceeds to complete FDA 510(k) filings for its debut range of TephaFLEX products. TephaFLEX, a polyester biomaterial made from a natural metabolite and which degrades "in a cell-friendly manner", is currently being developed by Tepha for several applications including suture, surgical mesh and patch products, tissue repair and tissue engineered cardiovascular devices.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.